Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for steroid-refractory chronic graft-versus-host disease
NL-OMON27822Phase 2Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Nov 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in chronic graft-versus-host disease (cGVHD), sponsored by University Medical Center Utrecht. Primary endpoint: Proportion of patients with a complete or partial response. Started Nov 2006; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NL-OMON27822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27822.